盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者的效果

doi:10.3760/cma.j.cn441417-20250102-12016

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (12): 2006-2010.DOI: 10.3760/cma.j.cn441417-20250102-12016

盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者的效果

高建东¹ 孙富德² 王奕皓³ 于洋⁴

¹烟台市烟台山医院疼痛科，烟台 264000；²蓬莱中医医院麻醉科，烟台 264000；³青岛大学附属医院平度院区疼痛科，青岛 266000；⁴青岛市市立医院疼痛科，青岛 266000

收稿日期:2025-01-02 出版日期:2025-06-15 发布日期:2025-06-15
通讯作者: 于洋，Email：yuyangck@163.com
基金资助:
山东省自然科学基金（ZR2022MH110）

Effect of tizanidine hydrochloride combined with venlafaxine in treatment of patients with chronic pain

Gao Jiandong¹, Sun Fude², Wang Yihao³, Yu Yang⁴

¹Department of Pain Management, Yantai City Yantaishan Hospital, Yantai 264000, China; ²Department of Anesthesia, Penglai Hospital of Traditional Chinese Medicine, Yantai 264000, China; ³Department of Pain Management, Pingdu Hospital, Hospital Affiliated to Qingdao University, Qingdao 266000, China; ⁴Department of Pain Management, Qingdao Municipal Hospital, Qingdao 266000, China

Received:2025-01-02 Online:2025-06-15 Published:2025-06-15
Contact: Yu Yang, Email: yuyangck@163.com
Supported by:
Shandong Natural Science Foundation (ZR2022MH110)

摘要/Abstract

摘要：

目的　探讨盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者的效果。方法　选取2021年4月至2023年4月烟台市烟台山医院收治的108例慢性疼痛患者进行随机对照试验。采用抽签法将其分为对照组和观察组，各54例。对照组男32例，女22例，年龄（44.64±4.18）岁，病程（1.65±0.57）年，体重指数（BMI）（23.05±1.08）kg/m2，疼痛位置：腰部10例，头部29例，四肢15例。观察组男30例，女24例，年龄（44.18±4.03）岁，病程（1.72±0.62）年，BMI（23.15±1.01）kg/m2，疼痛位置：腰部12例，头部27例，四肢15例。对照组盐酸替扎尼定治疗，观察组盐酸替扎尼定联合文拉法辛治疗。比较两组总有效率、疼痛评分、抑郁评分、焦虑评分、睡眠质量评分、生活质量及不良反应。采用χ2检验和t检验进行统计分析。结果　观察组总有效率高于对照组［94.44%（51/54）比79.63%（43/54）；χ2=5.252，P<0.05］。观察组治疗2周、治疗4周及治疗后3个月疼痛评分均低于对照组［（3.54±0.52）分比（4.42±1.01）分、（2.24±0.48）分比（3.05±0.84）分、（1.98±0.36）分比（3.45±0.79）分；t=5.692、6.152、12.442，均P<0.05）］。治疗后，观察组抑郁、焦虑、睡眠质量评分均低于对照组［（4.82±1.02）分比（7.42±1.42）分、（4.10±0.84）分比（7.05±1.03）分、（5.53±1.06）分比（8.42±1.84）分；t=10.927、16.310、10.001，均P<0.05］。治疗后，观察组躯体功能、心理功能、社会功能、物质生活状态、总体生活质量评分均高于对照组［（82.52±8.48）分比（75.45±7.19）分、（81.19±8.27）比（74.49±7.22）分、（82.82±8.51）分比（75.62±7.34）分、（80.05±8.28）分比（72.52±7.66）分、（81.69±8.28）分比（75.44±7.34）分；t=4.672、4.484、4.707、4.905、4.150，均P<0.05］。观察组与对照组不良反应发生率分别为9.26%（5/54）、7.41%（4/54），差异无统计学意义（χ2=0.121，P=0.727）。结论　盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者效果较好，不良反应少，可缓解患者抑郁和焦虑情绪，提高患者睡眠质量和生活质量。

关键词: 慢性疼痛, 替扎尼定, 文拉法辛, 疼痛程度, 抑郁, 焦虑, 不良反应

Abstract:

Objective　To investigate the effect of tizanidine hydrochloride and venlafaxine in the treatment of patients with chronic pain. Methods　One hundred and eight patients with chronic pain treated at Yantai City Yantaishan Hospital from April 2021 to April 2023 were selected for the randomized controlled trial, and were divided into a control group and an observation group by lottery, with 54 cases in each group. There were 32 males and 22 females in the control group; they were (44.64±4.18) years old; their disease course was (1.65±0.57) years; their body mass index was (23.05±1.08) kg/m²; 10 cases had pain on the lumbar, 29 the head, and 15 the limbs. There were 30 males and 24 females in the observation group; they were (44.18±4.03) years old; their disease course was (1.72±0.62) years; their body mass index was (23.15±1.01) kg/m²; 12 cases had pain on the lumbar, 27 the head, and 15 the limbs. The control group took tizanidine hydrochloride, and the observation group tizanidine hydrochloride and venlafaxine. The overall effective rates, scores of pain, depression, anxiety, and sleep quality, quality of life, and adverse reactions were compared between the two groups by χ² and t tests. Results　The total effective rate in the observation group was higher than that in the control group [94.44% (51/54) vs. 79.63% (43/54); χ²=5.252; P<0.05]. The pain scores after 2 weeks', 4 weeks' and 3 months' treatment in the observation group were lower than those in the control group (3.54±0.52 vs. 4.42±1.01, 2.24±0.48 vs. and 3.05±0.84, 1.98±0.36 vs. 3.45±0.79; t=5.692, 6.152, and 12.442; all P<0.05). After the treatment, the scores of depression, anxiety, and sleep quality in the observation group were lower than those in the control group (4.82±1.02 vs. 7.42±1.42, 4.10±0.84 vs. 7.05±1.03, and 5.53±1.06 vs. 8.42±1.84; t=10.927, 16.310, and 10.001; all P<0.05). After the treatment, the scores of somatic function, psychological function, social function, physical life status, and overall quality of life in the observation group were higher than those in the control group (82.52±8.48 vs. 75.45±7.19, 81.19±8.27 vs. 74.49±7.22, 82.82±8.51 vs. 75.62±7.34, 80.05±8.28 vs. 72.52±7.66, and 81.69±8.28 vs. 75.44±7.34; t=4.672, 4.484, 4.707, 4.905, and 4.150; all P<0.05). There was no statistical difference in the incidence rate of adverse reactions between the observation group and the control group [9.26% (5/54) vs. 7.41% (4/54); χ²=0.121; P=0.727]. Conclusion　Tizanidine hydrochloride and venlafaxine in the treatment of patients with chronic pain is effective and safe, and can relieve their depression and anxiety and improve their sleep quality and quality of life.

Key words: Chronic pain, , Tizanidine, , Venlafaxine, , Pain level, , Depression, , Anxiety, , Adverse reactions

高建东孙富德王奕皓于洋. 盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者的效果 [J]. 国际医药卫生导报, 2025, 31(12): 2006-2010.

Gao Jiandong, Sun Fude, Wang Yihao, Yu Yang.

Effect of tizanidine hydrochloride combined with venlafaxine in treatment of patients with chronic pain [J]. International Medicine and Health Guidance News, 2025, 31(12): 2006-2010.

参考文献

[1]孟超,张冰,于俊敏,等.普瑞巴林联合替扎尼定治疗带状疱疹后神经痛患者的疗效和安全性[J].中华疼痛学杂志,2021,17(2):186-190. DOI:10.3760/cma.j.cn101658- 20201117-00193.

[2]李金虎,顾芳,陈效曦,等.颈脊神经后支脉冲射频联合盐酸替扎尼定治疗颈源性头痛患者的效果及对血管内皮功能的影响[J].中国医学创新,2023,20(5):5-9. DOI:10.3969/j.issn.1674-4985.2023.05.002.

[3]章建新,郑建平,谢伟,等.替扎尼定治疗椎间盘源性腰痛患者的临床研究[J].中国临床药理学杂志,2021,37(8):970-973. DOI:10.13699/j.cnki.1001-6821.2021.08.009.

[4]王晓环,马占平,栗建辉,等.文拉法辛联合度洛西汀治疗老年躯体形式疼痛障碍临床研究[J].中国药业,2021,30(8):26-28. DOI:10.3969/j.issn.1006-4931.2021.08.007.

[5]严广斌. NRS疼痛数字评价量表numerical rating scale[J/OL].中华关节外科杂志(电子版),2014(3):410-410 [2025-01-02]. https://d.wanfangdata.com.cn/periodical/Ch9QZXJpb2RpY2FsQ0hJTmV3UzIwMjUwMTE2MTYzNjE0EhF6aGdqd2t6ejIwMTQwMzAzNBoIMnlydTJjM3I%3D.

[6]Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain [J]. Pain, 2019, 160(1): 53-59. DOI: 10.1097/j.pain.0000000000001365.

[7]沈显山,吴建贤,周云,等.汉密尔顿抑郁量表用于脑卒中后评定的最小可测变化值研究[J].中国康复医学杂志,2020,35(4):464-467. DOI:10.3969/j.issn.1001-1242. 2020.04.014.

[8]王纯,楚艳民,张亚林,等.汉密尔顿焦虑量表的因素结构研究[J].临床精神医学杂志,2011,21(5):299-301.

[9]路桃影,李艳,夏萍,等.匹兹堡睡眠质量指数的信度及效度分析[J].重庆医学,2014(3):260-263. DOI:10.3969/j.issn.1671-8348.2014.03.002.

[10]中国行为医学科学编辑委员会.行为医学量表手册[M].北京:中华医学电子音像出版社,2005: 77-90.

[11]许浩云,刘剑锋,伊金玲,等.盐酸文拉法辛缓释胶囊在中国健康受试者体内的药代动力学及生物等效性研究[J].中国临床药理学杂志,2023,39(2):271-275. DOI:10.13699/j.cnki.1001-6821.2023.02.025.

[12]李绍康,樊袁笑,曹晓雯,等.乌头汤加味联合盐酸替扎尼定片治疗椎间盘源性腰痛风寒瘀阻证临床观察[J].河北中医,2024,46(4):548-551,557. DOI:10.3969/j.issn.1002-2619. 2024.04.005.

[13]王玲娇,郭智敏,宋洋,等.川芎定痛胶囊联合文拉法辛治疗慢性偏头痛并抑郁障碍临床观察[J].中国药业,2023,32(12):94-97. DOI:10.3969/j.issn.1006-4931.2023.12.023.

[14]尹祖斌.文拉法辛对慢性疼痛于情绪障碍治疗的疗效观察[J].健康必读,2020(28):35.

[15]黄淑伟,田红杰,郭志勇,等.颈痛颗粒联合替扎尼定治疗神经根型颈椎病的疗效观察[J].现代药物与临床,2023,38(8):1948-1952. DOI:10.7501/j.issn.1674-5515.2023.08.019.

[16]刘畅,鲍观兴,杨舟.文拉法辛联合阿立哌唑对精神分裂症患者认知功能及PANSS评分的影响[J].上海医药,2023,44(16):18-21. DOI:10.3969/j.issn.1006-1533.2023.16.006.

[17]付晓敏.中药治疗慢性疼痛并发抑郁症和焦虑症的临床效果观察[J/OL].临床医药文献电子杂志,2023,10(36):70-73 [2025-01-02]. https://d.wanfangdata.com.cn/periodical/Ch9QZXJpb2RpY2FsQ0hJTmV3UzIwMjUwMTE2MTYzNjE0EhpRS0JKQkQyMDIzMjAyNDA3MTIwMDAwMTgzNxoIemhjMnB1Z3o%3D.

[18]包泽岩,陈修琼,胡琼力,等.盐酸替扎尼定联合盐酸文拉法辛治疗慢性紧张型头痛的临床效果[J].国际医药卫生导报,2021,27(16):2600-2603. DOI: 10.3760/cma.j.issn. 1007-1245.2021.16.044.

[19]赵飞飞,张君,李剑峰,等.替扎尼定联合利多卡因治疗腰椎术后疼痛综合征的临床研究[J].现代药物与临床,2024,39(10):2656-2660. DOI: 10.7501/j.issn.1674-5515. 2024.10.035.

[20]赵丽玲,黄彦珊,王利,等. SNRIs类药物在神经病理性疼痛中的临床应用进展[J].医药导报,2023,42(6):892-897. DOI: 10.3870/j.issn.1004-0781.2023.06.019.

[21]杜晨辉,刘露路,王珏,等.文拉法辛治疗中枢介导性腹痛综合征的临床研究[J].现代医药卫生,2020,36(8):1125-1127. DOI:10.3969/j.issn.1009-5519.2020.08.002.

[22]高清滢.文拉法辛联合托吡酯治疗偏头痛伴广泛性焦虑障碍患者的效果[J].中国民康医学,2023,35(1):28-30. DOI: 10.3969/j.issn.1672-0369.2023.01.009.

[23]袁春兰,黄振会,孔方方,等.针刺肌筋膜触发点技术联合替扎尼定治疗颈源性头痛的临床研究[J].现代医药卫生,2023,39(10):1675-1678,1684. DOI:10.3969/j.issn. 1009-5519.2023.10.013.

[24]刘洋,李静.文拉法辛联合普瑞巴林治疗躯体形式疼痛障碍抑郁症的效果[J].当代医学,2021,27(22):147-149. DOI: 10.3969/j.issn.1009-4393.2021.22.059.

[25]宋万智.替扎尼定联合文拉法辛缓释片治疗紧张性头痛的疗效分析[J].中国现代医生,2015,53(30):82-84.

盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者的效果

Effect of tizanidine hydrochloride combined with venlafaxine in treatment of patients with chronic pain

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李岩赵丽敏曲姗姗. 帕罗西汀联合茴拉西坦治疗老年抑郁症的疗效分析 [J]. 国际医药卫生导报, 2025, 31(9): 1544-1548.
[2]	杨玉凤卢立军邓倩陈士东王慧颖. 艾司西酞普兰联合舒肝解郁胶囊对老年抑郁症伴失眠的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1549-1553.
[3]	魏欣妍魏文娟可易弘钱海兵. 基于授权赋能理论的健康教育在类风湿性关节炎患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1569-1573.
[4]	马源吴冰莉张世珂李灿灿王子亮. 肠内营养在脑卒中吞咽障碍合并焦虑患者中的价值分析 [J]. 国际医药卫生导报, 2025, 31(8): 1306-1310.
[5]	刘杰王瑜牛永强. 独活续断汤离子导入对膝骨关节炎患者膝关节肿胀和疼痛程度的影响 [J]. 国际医药卫生导报, 2025, 31(7): 1098-1102.
[6]	张萍葛海英. 择时耳穴压豆+太极拳左右揽雀尾在脱出型腰椎间盘突出症患者中的应用 [J]. 国际医药卫生导报, 2025, 31(7): 1118-1122.
[7]	杨茂增蔡伟玲陆小兵梁耀国李一凡梁苑施. 血促肾上腺皮质激素及皮质醇水平与抑郁发作患者自杀风险的临床研究 [J]. 国际医药卫生导报, 2025, 31(5): 792-795.
[8]	付瑞舒忙巧王文栋郭新强王新荣康晓刚. 抑郁症伴精神病性症状与儿童期虐待的相关性分析及预测模型构建 [J]. 国际医药卫生导报, 2025, 31(3): 425-429.
[9]	韩冰王星赵斌邓传军刘宽. 超声引导下胸椎旁神经阻滞在单孔胸腔镜下肺叶切除术患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(3): 429-434.
[10]	郑瑶贾琳楠王智慧曲海丽丁鉴王宝月王平邢文静. β-内啡肽、环氧化酶-2与多巴胺受体D2对右向左分流偏头痛患者焦虑状况的预测价值 [J]. 国际医药卫生导报, 2025, 31(2): 284-288.
[11]	耿琳罗奋阳马现仓. 艾司西酞普兰联合重复经颅磁刺激在卒中后抑郁患者中的疗效分析 [J]. 国际医药卫生导报, 2025, 31(10): 1637-1640.
[12]	闫娟石昊安丽拓明祥王宏张彩峰何文娟李二乐. 虚拟现实技术联合前庭功能康复在周围性眩晕患者中的应用 [J]. 国际医药卫生导报, 2025, 31(10): 1665-1669.
[13]	段昆梅尚茜张红梅. 肺癌幸存者癌因性疲乏的特征及其与焦虑抑郁和应激相关激素的相关性研究 [J]. 国际医药卫生导报, 2025, 31(1): 132-135.
[14]	孙倩赵立成张晓嫚邵丽史进陈文姬王园园. 急性脑梗死患者抑郁和孤独在创伤后应激障碍与失能中的中介效应 [J]. 国际医药卫生导报, 2024, 30(9): 1513-1518.
[15]	卢健王亚军宋杰. 一次性根管治疗与多次法根管治疗在牙体牙髓病患者中的疗效观察 [J]. 国际医药卫生导报, 2024, 30(7): 1111-1116.